http://www.globenewswire.com/newsroom/?symbol=INFI GlobeNewswire: Infinity Pharmaceuticals, Inc. News en-us Copyright 2009, GlobeNewswire, Inc. Tue, 17 Nov 2009 13:00:00 GMT http://backend.userland.com/rss newsdesk@globenewswire.com (NewsDesk) webmaster@globenewswire.com (Webmaster) http://www.globenewswire.com/images/pzlogo_144x33.gif http://www.globenewswire.com/ 144 33 http://www.globenewswire.com/newsroom/news.html?ref=rss&d=178524 CAMBRIDGE, Mass., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=178524 Tue, 17 Nov 2009 13:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=178475 CAMBRIDGE, Mass., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on November 13, 2009 in New York City. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=178475 Mon, 16 Nov 2009 14:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=177990 CAMBRIDGE, Mass., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will present a company overview at two upcoming conferences. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=177990 Tue, 10 Nov 2009 12:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=177925 CAMBRIDGE, Mass., Nov. 9, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights and announced third quarter 2009 financial results. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=177925 Mon, 9 Nov 2009 21:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=177060 CAMBRIDGE, Mass., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that management will host a conference call on Monday, November 9, 2009 at 4:30 p.m. EST. In the conference call, management will review recent research and development and business highlights and Infinity's third quarter 2009 financial results. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=177060 Mon, 2 Nov 2009 11:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=174878 CAMBRIDGE, Mass., Oct. 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Thomas J. Lynch, Jr., M.D., has been appointed to its Board of Directors. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=174878 Wed, 7 Oct 2009 12:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=172445 CAMBRIDGE, Mass., Sept. 2, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will present a company overview at several upcoming conferences. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=172445 Wed, 2 Sep 2009 12:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=170763 CAMBRIDGE, Mass., Aug. 5, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights, provided updated 2009 guidance, and announced second quarter 2009 financial results. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=170763 Wed, 5 Aug 2009 21:15 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=170165 CAMBRIDGE, Mass., July 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Infinity management will host a conference call on Thursday, August 6, 2009 at 8:30 a.m. EDT. In the conference call, management will review recent research and development and business highlights including Infinity's second quarter 2009 financial results. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=170165 Thu, 30 Jul 2009 11:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=169714 CAMBRIDGE, Mass., July 23, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that the chemistry and data leading to the discovery of its novel Hedgehog signaling pathway inhibitor, IPI-926, have been published in the Journal of Medicinal Chemistry. The paper, titled "Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)" and authored by Infinity's Martin R. Tremblay, Ph.D., Alfredo C. Castro, Ph.D., et al., is featured in today's issue of the journal (Volume 52, Issue 14, pages 4400-4418). http://www.globenewswire.com/newsroom/news.html?ref=rss&d=169714 Thu, 23 Jul 2009 21:40 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=167998 CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it was added to the Russell 2000(r) Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 26, 2009. The Russell 2000, which is a subset of the Russell 3000(r) Index, measures the performance of the small-cap segment of U.S. equities. Membership in the Russell 2000 is reevaluated annually. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=167998 Mon, 29 Jun 2009 11:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=166313 ORLANDO, Fla. and CAMBRIDGE, Mass., May 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented promising data from two clinical trials of IPI-504, the company's heat shock protein 90 (Hsp90) chaperone inhibitor. Preliminary data from the Phase 2 portion of a study in patients with advanced non-small cell lung cancer (NSCLC) and a Phase 1 study of IPI-504 in combination with Taxotere(r) (docetaxel) demonstrate anti-tumor activity, including four partial responses in the Phase 2, and a generally well-tolerated safety profile in both studies. The data were presented during the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=166313 Sat, 30 May 2009 19:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=166260 CAMBRIDGE, Mass., May 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new scientific paper further supporting Hedgehog signaling pathway inhibition as a promising new approach to treat cancer. The data featured in the paper show that IPI-926, when administered in combination with gemcitabine in a preclinical mouse model of treatment-resistant pancreatic cancer, increased tumor cell death, resulting in a reduction of tumor size and increased survival. These data suggest that IPI-926 may enable chemotherapeutic agents to successfully access and kill tumor cells. Infinity is currently evaluating IPI-926 in a Phase 1 clinical trial in patients with advanced solid tumors. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=166260 Fri, 29 May 2009 11:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=166165 CAMBRIDGE, Mass., May 27, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has been named one of the "Best Places to Work" by both The Scientist and the Boston Business Journal. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=166165 Wed, 27 May 2009 18:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=165286 CAMBRIDGE, Mass., May 13, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting clinical data on its novel Hsp90 chaperone inhibitor, IPI-504, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Fla. from May 29 through June 2, 2009. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=165286 Wed, 13 May 2009 12:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=164564 CAMBRIDGE, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent clinical developments, reaffirmed its commitment to advancing its Hsp90 chaperone inhibitor program, provided updated 2009 guidance, and announced first quarter 2009 financial results. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=164564 Mon, 4 May 2009 21:30 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=164035 CAMBRIDGE, Mass., April 28, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management will host a conference call on Tuesday, May 5, 2009 at 8:30 a.m. EDT. In the conference call, management will review recent clinical and business developments and discuss Infinity's first quarter 2009 results. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=164035 Tue, 28 Apr 2009 15:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=163481 DENVER, Colo. and CAMBRIDGE, Mass., April 21, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented data from its heat shock protein 90 (Hsp90) inhibitor program that supports the scientific rationale for Infinity's recently initiated Phase 2 study in breast cancer, and further enhances Infinity's scientific leadership in the field of Hsp90 inhibition. The data were presented during the 2009 American Association of Cancer Research (AACR) Annual Meeting in Denver. Infinity is developing two Hsp90 inhibitors: IPI-504, which is in Phase 2 clinical development, and its oral Hsp90 inhibitor, IPI-493, which is in Phase 1 clinical development. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=163481 Tue, 21 Apr 2009 20:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=163466 DENVER and CAMBRIDGE, Mass., April 21, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented preclinical data from studies of IPI-926, its oral Hedgehog pathway inhibitor that targets Smoothened, during the 2009 American Association of Cancer Research (AACR) Annual Meeting in Denver, Colo. The data presented further elucidate the promising role of Hedgehog pathway inhibition in addressing a broad range of cancers, including those that are Hedgehog ligand-independent as well as Hedgehog ligand-dependent. IPI-926 is currently in Phase 1 clinical development. http://www.globenewswire.com/newsroom/news.html?ref=rss&d=163466 Tue, 21 Apr 2009 15:00 GMT http://www.globenewswire.com/newsroom/news.html?ref=rss&d=163098 CAMBRIDGE, Mass., April 15, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that, based on the recommendation of its independent data monitoring committee (IDMC), Infinity has elected to terminate the RING trial, a double-blind, placebo-controlled international Phase 3 registration trial of IPI-504 (retaspimycin hydrochloride) in patients with refractory gastrointestinal stromal tumors (GIST). http://www.globenewswire.com/newsroom/news.html?ref=rss&d=163098 Wed, 15 Apr 2009 14:15 GMT